

1 **Detection of SARS-CoV-2 infection in gargle, spit and sputum specimens**

2

3 Eero Poukka ^{1*}, Henna Mäkelä ^{1*}, Lotta Hagberg ², Thuan Vo ^{1,3}, Hanna Nohynek ¹, Niina Ikonen ²,
4 Kirsi Liitsola ², Otto Helve¹, Carita Savolainen-Kopra ², Timothée Dub ¹

5 1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish

6 Institute for Health and Welfare (THL), Helsinki, Finland

7 2. Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and

8 Welfare (THL), Helsinki, Finland

9 3. Health Sciences Unit, Faculty of Social Sciences, University of Tampere, Tampere, Finland

10 * Both authors contributed equally

11

12 Word count: 2154 (Methods included)

13 **Abstract**

14 The gold standard for SARS-CoV-2 infection diagnosis is RT-PCR from nasopharyngeal specimen
15 (NPS). Its collection involves a close contact between patients and healthcare workers requiring a
16 significant amount of workforce and putting them at risk of infection. We evaluated self-collection
17 of alternative specimens and compared their sensitivity and Ct values to NPS. We visited acute
18 COVID-19 outpatients to collect concomitant nasopharyngeal and gargle specimens and had
19 patients self-collect a gargle and either sputum or spit specimens on the next morning.

20 We included 40 patients and collected 40 concomitant nasopharyngeal and gargle specimens, as
21 well as 40 gargle, 22 spit and 16 sputum specimens on the next day, as 2 patients could not

22 produce sputum.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 All specimens were as sensitive as NPS. Gargle specimens had a sensitivity of 0.97 (CI 95% 0.92-
24 1,00), whether collected concomitantly to NPS or on the next morning. Next morning spit and
25 sputum specimens showed a sensitivity of 1.00 CI (95% 1.00-1.00) and 0.94 (CI 95% 0.87-1.00),
26 respectively. The gargle specimens had a significantly higher mean cycle threshold (Ct) values,
27 29.89 (SD 4.63) (p-value <0.001) and 29.25 (SD 3.99) (p-value <0.001) when collected
28 concomitantly and on the next morning compared to NPS (22.07, SD 4.63). Ct value obtained with
29 spit (23.51, SD 4.57, p-value 0.11) and sputum (25.82, SD 9.21, p-value 0.28) specimens were close
30 to NPS.

31 All alternative specimen collection methods were as sensitive as NPS, but spit collection appeared
32 more promising, with a low Ct value and ease of collection. Our findings warrant further
33 investigation.

34

35 **Introduction**

36 In December 2019, SARS-CoV-2 emerged from the Chinese city of Wuhan (1). The disease spread
37 into countries outside China and was declared a global pandemic in March 2020 (2). Within a year,
38 more than 115 million COVID-19 cases were confirmed, including two and a half million deaths
39 (3).

40 The SARS-CoV-2 pandemic control relies on a test-trace-isolate strategy with early diagnosis and
41 isolation of infected individuals and identification of their contacts (4) which has led to an initial
42 shortage of personal protective and sampling equipment, as well as increasing healthcare workers'
43 workload (6,7). Alone in Finland, a country with approximately 5 500 000 inhabitants, by the 20th

44 of March 2021 over 3 700 000 tests, of which 145 000 during the first week of March 2021, were
45 conducted and analyzed nationwide during the COVID-19 pandemic (5,6).

46 Collection of nasopharyngeal specimen (NPS) is the gold standard for SARS-CoV-2 infection
47 diagnosis (7). However, it is an unpleasant procedure requiring a close contact with HCW with a
48 risk of discomfort and in worst cases, epistaxis for the patient, and infections exposure for the
49 HCW (8,9). The use of an alternative specimen collection method could increase specimen
50 collection and testing capacities as well as decrease HCWs' workload and risk for infection (8).
51 There has been several studies evaluating alternative specimen collection methods but none of
52 the specimen collection methods have yet superseded NPS (10–13), even though one Finnish
53 private healthcare provider now offers asymptomatic patients the possibility to self-collect a
54 gargle specimen as an alternative to NPS (14).

55 We evaluated and compared three alternative specimen collection methods that would not
56 require close contact to a HCW and compared their sensitivity and Ct values to NPS.

57

58 **Materials and methods**

59 We contacted confirmed COVID-19 outpatients who had been diagnosed with SARS-CoV-2
60 infection by RT-PCR (reverse transcription polymerase chain reaction) on NPS a few days earlier.
61 Children under 2 years old were not eligible for participation. After calling the patient for
62 recruitment, we visited them on the same and following day.

63 During the first home visit, we gathered informed consent, gave participants a link to an online
64 symptom- questionnaire and collected a NPS and gargle specimen (gargle 1). We also gave them
65 instructions and containers for collection of gargle (gargle 2) and, depending on the recruitment

66 week, sputum or spit specimen on the next morning. On the following day, the patients collected
67 themselves the second gargle (gargle 2) and either spit or sputum specimens. The next day the
68 self-collected specimens were collected. The timeline of the study is presented in Figure 1.

69 All alternative specimens were collected into a 70 ml plastic container. To collect the gargle
70 specimens, the patients were asked to have sip of water, and gargle it for 5-20 seconds before
71 spitting it in the container. For spit collection, the patients were asked to spit continuously into the
72 container until filled to half its volume, and with sputum specimen they were asked to cough
73 sputum deep from their lungs and then spit it into the container. Both the spit and sputum
74 specimens were advised to be collected in the morning before the patients ate, drunk or brushed
75 their teeth.

76 All specimens were transported at room temperature and analyzed on the same day in Expert
77 Microbiology unit at the Finnish Institute for Health and Welfare (THL).

78 The Finnish communicable diseases law and the law on the duties of THL allows the
79 implementation of this noninvasive research without seeking further ethical approval (THL-laki 5 e
80 §; Tartuntatautilaki 7 § and 23 §).

81 ***Laboratory methods***

82 RNA extraction from samples was performed using Chemagic Viral300 DNA/RNA Kit H96 (PerkinElmer)
83 according to the manufacturer's instructions. A sample volume 300 µl and an elution volume 50 µl
84 were used. Highly viscose gargle samples were vortexed with 1 ml PBS before taking 300 µl for
85 RNA extraction. Real time RT PCR was performed using qScript™ XLT One-Step RT-qPCR
86 ToughMix® (Quantabio). SARS-CoV-2 was detected using the E (envelope) gene real-time RT-PCR
87 assay. Primers and probes were based on the Corman E gene premier/probe set(15). The thermal

88 profile for PCR was 55°C for 20 min and 95°C for 3 min, followed by 45 cycles at 95°C 15 s and
89 58 °C 1 min using CFX thermal cycler (BioRad).

90 **Statistical analysis**

91 We used NPS RT-PCR test results as reference method and Ct values as surrogates for viral load
92 analysis. We performed paired t-test or Wilcoxon signed-rank test to compare the measured Ct
93 values between nasopharyngeal and gargle, and between nasopharyngeal and sputum/spit
94 specimens. Standard methods were used to calculate sensitivity and specificity of the other
95 diagnostic tests (index tests) from saliva- and sputum/spit specimens. Exact McNemar’s test was
96 used to assess the differences in sensitivity and specificity.

97 We calculated Cohen’s kappa coefficient to evaluate the agreement between the reference and
98 the index tests. Area under a receiver operating characteristic curve (AUC) and 95% CI were
99 reported. Because of the imperfect reference test, latent class analysis was used as a correction
100 method to adjust the estimated sensitivity and specificity of the index tests based on the existing
101 sensitivity and specificity of the reference test. Model selection was based on Bayesian
102 information criterion (BIC). Data analysis was performed using R software (version. 3.6.0).

103

104 **Results**

105 We enrolled 40 patients with a mean age of 38.7 years old (SD: 12.6) including 21 (53%) females.
106 Enrolment was done as soon as they received the positive testing results, either one day (n=27/40,
107 67.5%) or two days (n=13/40, 32.5%) after they had been NPS sampled for COVID-19 diagnosis.
108 Thirty-one patients had been symptomatic since disease onset (supplementary table 1) with most
109 prevalent symptoms being fatigue (86%), headache (81%) and cough (79%). At the time of

110 specimen collection, only 24 patients were symptomatic with the most prevalent being cough
111 (44%), anosmia (42%) and headache (40%).

112 We collected 40 concomitant nasopharyngeal and gargle specimens on recruitment day, as well as
113 40 next morning gargle specimens. Out of 22 patients assigned to the spit specimen collection
114 group, all of them gave back specimens, while out of 18 patients assigned to the sputum group,
115 two patients could not produce sputum.

116 All specimens were generally as sensitive as NPS to diagnose SARS-CoV-2 infection in our study
117 population. The spit specimen showed the highest sensitivity (sensitivity 1.00 CI 95 % 1.00-1.00),
118 followed by gargle specimens, regardless of when they were collected: 0.97 (CI 95 % 0.92-1.00).
119 The sputum specimen had the lowest sensitivity (0.94 CI 95 % 0.87-1.00).

120 We compared Ct values obtained from alternative specimens to NPS (Table 2). NPS had the lowest
121 Ct value (22.07, SD 4.63), although it was not significantly lower compared to sputum (25.82, SD
122 9.21), (p-value 0.28) and spit (23.51, SD 4.57), (p-value 0.11) specimens. Both gargle specimens
123 had statistically significantly higher Ct values, compared to NPS (Table 2).

124 All patients' different specimens' results are presented in supplementary figures 1-4.

125

126 **Discussion**

127 We evaluated self-collection of alternative specimens: gargle, spit and sputum and compared their
128 sensitivity and Ct values to NPS specimens as alternative methods for SARS-CoV-2 infection
129 diagnosis. All specimen collection methods were as sensitive as NPS, with sensitivities exceeding
130 90 %. In comparison with NPS, the gargle specimens had higher Ct values, likely due to dilution by
131 gargling water. Therefore in milder cases with low viral load, it might not be as sensitive as NPS.

132 Spit and sputum specimens collected on the following day had a higher though not significantly
133 different Ct value compared to NPS, however, sputum appeared more challenging to collect in
134 patients with milder symptoms. Hence, spit would appear as the most suitable alternative
135 specimen to NPS for SARS-CoV-2 infection diagnosis.

136 Since the beginning of the COVID-19 pandemic, several studies or meta-analysis have investigated
137 the potential use of saliva specimen for SARS-CoV-2 infection diagnosis among both symptomatic
138 (8,9,11,16–21) and asymptomatic patients (8,9,11,16–18,21,22). ECDC and CDC have approved
139 the use of saliva or sputum as a diagnostic specimen for COVID-19 for patients with a productive
140 cough (23,24).

141 There has been mixed results considering difference in Ct levels between NPS and saliva
142 specimens (11,19,20,22). These inconclusive results can be caused by various factors: morning
143 saliva might have higher viral load compared to the rest of the day (18), levels of SARS-CoV-2 virus
144 in saliva correlate to COVID-19 symptoms severity (25). Additionally, early-morning posterior
145 oropharyngeal spitting technique has been considered to have higher sensitivity for SARS-CoV-2
146 infection diagnosis compared to NPS (8).

147 Previously, gargle specimens have also been estimated sensitive for SARS-CoV-2 infection
148 diagnosis compared to NPS including 50 inpatients (26) and outpatients (10,27) with confirmed
149 COVID-19. Ct values of gargle specimens were higher than in NPS in these three studies including
150 one with 19 620 outpatients which is in line with findings in our study (10,26,27). Interestingly
151 Goldfard et al, when analyzing 40 COVID-19 outpatients concluded that gargle specimens had
152 higher sensitivity compared to saliva specimens (97.5 % CI 86.8-99.9 % compared to 78.8 CI 95 %
153 61.0-91.0 %) which is inconsistent with our results, although saliva collection methods were similar
154 (10).

155 Levican et al and Malczynski et al showed that diagnostic results and Ct values were comparable
156 between sputum and nasopharyngeal tests during the first ten days after COVID-19 diagnosis in
157 study population of 82 and 50 hospitalized patients, respectively (28,29). The result was also
158 consistent with this study.

159 Alternative specimens' collection main benefit compared to NPS would be to avoid close contact
160 with a HCW, to allow participants to collect the specimen themselves and to avoid an unpleasant
161 procedure. Overall, it would also increase the willingness to apply for SARS-CoV-2 testing and
162 allocation of current resources in HCWs.

163 The main limitations of our work are that we did not analyse whether delayed transport or
164 extended storage before analysis could hamper sensitivity as all samples were transported and
165 processed on the very same day and our low sample size (40 participants in total), however we
166 conducted this study as an exploratory assessment of alternative specimen collection. We focused
167 on patients with the most common clinical picture of COVID-19: mild symptoms, as they are the
168 ones that would most benefit from non-invasive alternative specimen collection. An additional
169 strength was that all samples were collected within 1-2 days after diagnosis, while patients were
170 still at the acute phase of the disease.

171

172 **Conclusion**

173 Among gargle, spit and sputum specimens, morning collection of approximately 30 mL of spit
174 before any food and water intake or teeth brushing appeared to be the most suitable alternative
175 specimen collection method with a Ct-value as low as obtained with NPS and ease of collection for
176 patients with mild symptoms. Our findings were promising but warrant further investigations with

177 larger study population. We will consider offering the possibility to patients with mild symptoms
178 seeking diagnosis in a pilot testing centre, the possibility to enroll in a study assessing whether in
179 general population, spit collected on the next morning has the same performance as in our
180 exploratory sample. If so, in the long run, we could offer patients with mild symptoms to choose
181 between at home self-collection of spit versus nasopharyngeal specimen collection at a testing
182 centre. Not only would it decrease discomfort, but also decrease HCWs' exposure and burden.

183 **Acknowledgements**

184 The authors thank Helsinki city and Helsinki city's Epidemiological Unit for sharing data of the
185 COVID-19 patients. We are also grateful to THL Virology laboratory staff who analyzed the
186 specimens among other works.

187 **Conflict of interest**

188 None to declare.

189 **Author's contributions**

190 Study design: Henna Mäkelä, Lotta Hagberg, Thuan Vo, Hanna Nohynek, Niina Ikonen, Otto Helve,
191 Carita Savolainen-Kopra and Timothée Dub.

192 Statistical analysis: Thuan Vo

193 Specimen collection and logistics: Eero Poukka, Henna Mäkelä, Lotta Hagberg and Timothée Dub.

194 Laboratory analysis: Niina Ikonen, Kirsi Liitsola and THL Virology laboratory.

195 Writing and editing: All authors.

196

198 **Reference**

- 199 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
200 Pneumonia in China, 2019. *N Engl J Med.* 2020 20;382(8):727–33.
- 201 2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020
202 [Internet]. [cited 2020 Dec 3]. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
203 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
204 [covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 205 3. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2021 Mar 4]. Available
206 from: <https://covid19.who.int>
- 207 4. European Centre for Disease Prevention and Control. Contact tracing: public health
208 management of persons, including healthcare workers, who have had contact with COVID-19
209 cases in the European Union – third update. ECDC; 2020.
- 210 5. Finnish Institute for Health and Welfare. COVID-19-epidemia hybridistategian seuranta –
211 tilannearvio raportti 10.3.2021. THL; 2021.
- 212 6. Tilannekatsaus koronaviruksesta - Infektioaudit ja rokotukset - THL [Internet]. Terveystien ja
213 hyvinvoinnin laitos. [cited 2021 Mar 22]. Available from: [https://thl.fi/fi/web/infektioaudit-ja-](https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/tilannekatsaus-koronaviruksesta)
214 [rokokukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/tilannekatsaus-](https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/tilannekatsaus-koronaviruksesta)
215 [koronaviruksesta](https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/tilannekatsaus-koronaviruksesta)
- 216 7. World Health Organization (WHO). Diagnostic testing for SARS-CoV-2: Interim guidance. 2020
217 Sep 11;
- 218 8. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for
219 SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and
220 Meta-analysis. *Ann Intern Med.* 2021 Jan 12;
- 221 9. Medeiros da Silva RC, Nogueira Marinho LC, Neto de Araújo Silva D, Costa de Lima K, Pirih FQ,
222 Luz de Aquino Martins AR. Saliva as a possible tool for the SARS-CoV-2 detection: a review.
223 *Travel Med Infect Dis.* 2020 Nov 18;101920.
- 224 10. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, et al. Self-collected Saline
225 Gargle Samples as an Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for
226 COVID-19 Diagnosis in Outpatients. *J Clin Microbiol.* 2021 Jan 29;JCM.02427-20,
227 [jcm;JCM.02427-20v1](https://doi.org/10.1128/JCM.02427-20v1).
- 228 11. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.
229 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med.* 2020
230 24;383(13):1283–6.
- 231 12. Malecki M, Lüsebrink J, Teves S, Wendel AF. Pharynx gargle samples are suitable for SARS-CoV-
232 2 diagnostic use and save personal protective equipment and swabs. *Infect Control Hosp*
233 *Epidemiol.* 2020 May 11;1–2.


- 234 13. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of
235 Clinical Specimens. *JAMA*. 2020 12;323(18):1843–4.
- 236 14. Koronatesti kurlaamalla - Terveystalo [Internet]. [cited 2021 Mar 25]. Available from:
237 <https://www.terveystalo.com/fi/Tietopaketti/Koronatesti-kurlaamalla/>
- 238 15. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
239 coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* [Internet]. 2020 Jan 23 [cited
240 2021 Mar 22];25(3). Available from:
241 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045>
- 242 16. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et al. Saliva as a Candidate for COVID-
243 19 Diagnostic Testing: A Meta-Analysis. *Front Med (Lausanne)*. 2020;7:465.
- 244 17. Sagredo-Olivares K, Morales-Gómez C, Aitken-Saavedra J. Evaluation of saliva as a
245 complementary technique to the diagnosis of COVID-19: a systematic review. *Med Oral Patol*
246 *Oral Cir Bucal*. 2021 Feb 20;
- 247 18. Hung DL-L, Li X, Chiu KH-Y, Yip CC-Y, To KK-W, Chan JF-W, et al. Early-Morning vs Spot Posterior
248 Oropharyngeal Saliva for Diagnosis of SARS-CoV-2 Infection: Implication of Timing of Specimen
249 Collection for Community-Wide Screening. *Open Forum Infectious Diseases*. 2020 Jun
250 1;7(6):ofaa210.
- 251 19. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a Noninvasive Specimen for
252 Detection of SARS-CoV-2. *J Clin Microbiol*. 2020 Jul 23;58(8).
- 253 20. Yokota I, Hattori T, Shane PY, Konno S, Nagasaka A, Takeyabu K, et al. Equivalent SARS-CoV-2
254 viral loads by PCR between nasopharyngeal swab and saliva in symptomatic patients. *Sci Rep*.
255 2021 Feb 24;11(1):4500.
- 256 21. Butler-Laporte G, Lawandi A, Schiller I, Yao M, Dendukuri N, McDonald EG, et al. Comparison
257 of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-
258 CoV-2: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2021 Mar 1;181(3):353–60.
- 259 22. Herrera LA, Hidalgo-Miranda A, Reynoso-Noverón N, Meneses-García AA, Mendoza-Vargas A,
260 Reyes-Grajeda JP, et al. Saliva is a reliable and accessible source for the detection of SARS-CoV-
261 2. *Int J Infect Dis*. 2021 Feb 11;105:83–90.
- 262 23. CDC. Labs [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Feb 22].
263 Available from: [https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)
264 [specimens.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)
- 265 24. Diagnostic testing and screening for SARS-CoV-2 [Internet]. European Centre for Disease
266 Prevention and Control. [cited 2021 Mar 24]. Available from:
267 <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing>
- 268 25. Silva J, Lucas C, Sundaram M, Israelow B, Wong P, Klein J, et al. Saliva viral load is a dynamic
269 unifying correlate of COVID-19 severity and mortality. *medRxiv*. 2021 Jan 10;

- 270 26. Mittal A, Gupta A, Kumar S, Surjit M, Singh B, Soneja M, et al. Gargle lavage as a viable
271 alternative to swab for detection of SARS-CoV-2. *Indian J Med Res.* 2020 Aug;152(1 & 2):77–
272 81.
- 273 27. Kandel CE, Young M, Serbanescu MA, Powis JE, Bulir D, Callahan J, et al. Detection of severe
274 acute respiratory coronavirus virus 2 (SARS-CoV-2) in outpatients: A multicenter comparison of
275 self-collected saline gargle, oral swab, and combined oral–anterior nasal swab to a provider
276 collected nasopharyngeal swab. *Infect Control Hosp Epidemiol.* 2021 Jan 13;1–5.
- 277 28. Levican-Asenjo JE, Almonacid LI, Valenzuela G, Garcia T, Rojas L, Serrano E, et al. Viral shedding
278 dynamics reveals sputum as a reliable and cost-saving specimen for SARS-CoV-2 diagnosis
279 within the first 10 days since symptom onset: A prospective cohort study. *medRxiv.* 2020 Sep
280 1;
- 281 29. Malczynski M, Rezaeian S, Rios J, Dirnberger L, Polanco W, Zembower T, et al. Development of
282 a protocol for detection of SARS-CoV-2 in sputum and endotracheal aspirates using Cepheid
283 Xpert Xpress SARS-CoV-2. *Access Microbiol.* 2020;2(12):acmi000176.

284

285

286 **Tables and figures**



287

288 **Figure 1.** Timeline of the study. NPS =Nasopharyngeal specimen.

	NPS		Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (corrected)	Specificity (corrected)	Cohen's kappa (95% CI)	AUC (95% CI)
	+	-						
Gargle 1	+	37	0.97 (0.92, 1.00)	0.50 (0.00, 1.00)	0.97 (0.02, 1.00)	0.50 (0.00, 1.00)	0.47 (-0.15, 1.00)	0.74 (0.47,1.00)
	-	1						
Gargle 2	+	37	0.97 (0.92, 1.00)	0.50 (0.00, 1.00)	1.00 (1.00, 1.00)	1.00 (0.87, 1.00)	0.47 (-0.15, 1.00)	0.74 (0.47,1.00)
	-	1						
Sputum	+	13	0.94 (0.83, 1.00)	0	-	-	-0.09 (-0.22, 0.04)	0.54 (0.50, 0.61)
	-	2						
Spit	+	21	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	-	-	1.00 (1.00, 1.00)	1 (1,1)
	-	0						

289 **Table 1.** Sensitivity and specificity of tested sampling methods

Sample	n	Mean (SD)/	p-value
Nasopharyngeal	40	22.07 (4.63)	Ref
Gargle 1	40	29.89 (4.34)	< 0.001 ^a
Gargle 2	40	29.25 (3.99)	< 0.001 ^a
Sputum	16	25.82 (9.21)	0.28 ^a
Spit	22	23.51 (4.57)	0.11 ^a

^a Paired t-test
^b Wilcoxon signed-rank test

290 **Table 2:** Comparison of Ct-values obtained with alternative samples to nasopharyngeal samples.

291



Instructions for sampling gargle, spit and sputum

Gargle sample


- Have a sip of water (1/4 of a glass)
- Gargle
- Spit is back in the container
- Close the container
- Seal it in the zypbag

Spit sample

- Upon waking up, avoid food, water and brushing your teeth until the spit sample is collected
- Repeatedly spit into the container until it is half full with liquid (excluding bubbles)
- Securely close the container
- Store at room temperature

Sputum sample

- Lean forward and cough hard to get tough mucus from the lower airways.
- Approximately tablespoon of mucus is enough to sample
- Close the container and put the container back to the zypbag seal it carefully.
- Store the container in the refrigerator until the samples are retrieved.



292

293 **Attachment 1. Instructions for sampling gargle, spit and sputum**


294

	Symptoms experienced since COVID-19 onset N (%)	Symptoms at the time of sample collection N (%)
Any symptoms	31 (86)	24 (67%)
Fever	21 (60)	6 (19)
Sore throat	19 (56)	11 (32)
Cough	27 (79)	15 (44)
Runny nose	22 (65)	12 (34)
Shortness of breath	5 (16)	2 (6)
Chills	26 (76)	7 (20)
Vomiting	0 (0)	0 (0)
Nausea	6 (17)	3 (9)
Diarrhea	9 (24)	3 (9)
Headache	29 (81)	14 (40)
Neurological signs	2 (6)	1 (3)
Rash	2 (6)	2 (6)
Conjunctivitis	0 (0)	0 (0)
Muscle ache	25 (69)	12 (36)
Joint ache	7 (20)	5 (15)
Loss of appetite	13 (36)	12 (35)
Nose bleeding	0 (0)	0 (0)
Fatigue	31 (86)	25 (71)
Malaise	16 (44)	13 (38)
Seizure	0 (0)	0 (0)
Altered conscious	2 (6)	2 (6)
Anosmia	14 (44)	14 (42)
Other	9 (26)	4 (13)

295 **Supplementary table 1. Symptoms reported by patients**

296


297



298


299 **Figure 2. Ct-values from gargle 1 and nasopharyngeal sample by each participant**

300




301

302 **Figure 3. Ct-values from gargle 2 and nasopharyngeal sample by each participant**



303

304 **Figure 4. Ct- values from spit sample and nasopharyngeal sample by each participant**



305

306 **Figure 5. Ct-values from sputum sample and nasopharyngeal sample by each participant**

307